← Research & Industry News
External source
Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3)
In part three of our series, I spoke with Ryan Confer, President and CEO of Genprex, about the company’s move from cancer into diabetes.
- Published by
- Labiotech.eu
- Evidence type
- Industry
In part three of our series, I spoke with Ryan Confer, President and CEO of Genprex, about the company’s move from cancer into diabetes.
This item was selected automatically by our daily literature and news monitor because it matches the topics we follow. Read the full story at Labiotech.eu.
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.